Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256711
Status:
COMPLETED
Last Update Posted:
2009-04-23
First Post:
2005-11-20
Brief Title:
Phase II Iressa Versus Vinorelbine INVITE
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Open Label Parallel Group Multi-Centre Phase II Study of Progression Free Survival Comparing ZD1839 IRESSA 250 MG Tablet Versus Vinorelbine 30 MGM2 Infusion in Chemonaive Elderly Patients With Locally Advanced Stage IIIB or Metastatic Stage IV NSCLC
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized open label parallel group multi-centre phase II study of progression free survival comparing oral ZD1839 IRESSA 250 mg tablet once daily to vinorelbine 30 mgm2 infusion on days 1 and 8 of a 21-day cycle in chemonaïve elderly patients with locally advanced stage IIIB or metastatic stage IV non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| INVITE | None | None | None |